A batch of heavyweight drugs first reviewed: Tianshili, Hengrui, Shiyao (list attached)

Source: announcement of listed pharmaceutical companies ▍ finishing: Cypress blue corn 9 big varieties, the first one ever evaluated On November 13, Jiangsu Deyuan Pharmaceutical Co., Ltd released the announcement on the consistency evaluation of 0.12g nateglinide tablets through generic drugs, announcing that nateglinide tablets (trade name "tangrui") had the first evaluation According to the public information, Nateglinide is a nonsulfonylurea insulin secretagogue agent By binding and shutting down the ATP sensitive K + channel receptor on the cell membrane, it can depolarize the cell, open the calcium channel and flow in calcium, thus stimulating the secretion of insulin and reducing blood sugar Nateglinide tablets were first developed jointly by Ajinomoto Co., Ltd and Astaire Pharmaceutical Co., Ltd and approved for listing in Japan in 1999 Subsequently, the license holding right of nateglinide was transferred to Novartis, which was approved by FDA in December 2000 and EU in April 2001 In China, Beijing Novartis Pharmaceutical Co., Ltd obtained approval for the listing of nateglinide tablets in 2003 According to the Chinese Pharmaceutical Association hospital medication database (CPA data), the sales volume of nateglinide in the domestic sample market in 2018 was 25.6788 million yuan This is another first evaluated drug In the past two months, there have been eight first evaluated drugs released On November 8, Shandong Lukang Pharmaceutical released the notice on conformity evaluation of drugs passing generic drugs, saying that it received the approval document for supplementary application of amoxicillin capsule (approval No.: 2019b04059, 2019b04060) issued by the State Drug Administration, and the drug (0.25g and 0.125g) passed the conformity evaluation of quality and efficacy of generic drugs Among them, 0.125g is the first one In 2018, the domestic sales of amoxicillin capsule was about 2.4 billion yuan, and the sales revenue of Lukang product was 146 million yuan On November 7, Jiangsu Enhua Pharmaceutical Co., Ltd issued the announcement on clozapine tablets passing the consistency evaluation, announcing that clozapine tablets (25mg) passed the consistency evaluation It is reported that this variety of antipsychotics is mainly used to treat refractory schizophrenia Data showed that clozapine tablets (25mg) were the first to be evaluated On November 6, Jiangsu Hengrui Pharmaceutical Co., Ltd issued the announcement on the company's drugs passing the conformity evaluation of generic drugs It said that it had received the approval document of drug supplement application for letrozole tablets approved and issued by the State Food and drug administration, and announced that letrozole tablets (2.5mg) passed the consistency evaluation in the first batch On October 6th, Yiling Pharmaceutical Co., Ltd of Shijiazhuang issued the announcement on the conformity evaluation of Ciprofloxacin Hydrochloride Tablets, and received the approval of drug supplement application for Ciprofloxacin Hydrochloride Tablets (0.25g) approved and issued by the State Drug Administration The variety passed the conformity evaluation On November 2, Chengdu Kanghong Pharmaceutical Co., Ltd issued the announcement on the approval of venlafaxine hydrochloride sustained-release tablets for drug supplement application After examination, the venlafaxine hydrochloride sustained-release tablets (75mg) declared by Kanghong Pharmaceutical Co., Ltd passed the consistency evaluation of quality and efficacy of generic drugs It is reported that venlafaxine hydrochloride sustained-release tablet is a national essential drug (2018 version) category At present, only Kanghong pharmaceutical products have been approved for listing in China On October 31, Sinopharm group announced that ibuprofen granules (0.2g) developed by its subsidiary, Sinopharm group Ouyi Pharmaceutical Co., Ltd., had been approved by China National Drug Administration to pass the quality and efficacy consistency evaluation of generic drugs It is also the first similar product in China to pass the consistency evaluation On October 23, TSL Pharmaceutical Group announced that its wholly-owned subsidiary, Jiangsu TSL Diyi Pharmaceutical Co., Ltd., had received the supplementary approval for drugs (approval No.: 2019b03973) on the 3mg specification of youzopiclone tablet issued by the State Drug Administration The drug passed the consistency evaluation of generic drugs and was the first one in China to pass the consistency evaluation According to the latest data of iqvia CHPA, the drug sales of youzopiclone's domestic sample hospitals in 2018 was 209 million people, an increase of 29.5% over the same period in 2017 On October 17, Shanghai Hyundai pharmaceutical announced that its wholly-owned subsidiary, Sinopharm Shantou Jinshi Pharmaceutical Co., Ltd., had received the approval document for supplementary application of cefuroxime axetil tablets (0.5g) approved and issued by the State Food and drug administration, and approved the drug to pass the conformity evaluation of quality and efficacy of generic drugs According to the data of PDB drug comprehensive database, the global sales of cefuroxime axetil tablets in 2018 was $664 million, down 1.45% year on year In 2018, the sales revenue of Jinshi cefuroxime ester tablets (0.5g) was about 8.04 million yuan.